493 related articles for article (PubMed ID: 32982407)
1. PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date.
Nizialek E; Antonarakis ES
Cancer Manag Res; 2020; 12():8105-8114. PubMed ID: 32982407
[TBL] [Abstract][Full Text] [Related]
2. The emerging role of PARP inhibitors in prostate cancer.
Stellato M; Guadalupi V; Sepe P; Mennitto A; Claps M; Zattarin E; Verzoni E; Valdagni R; De Braud FG; Santini D; Tonini G; Procopio G
Expert Rev Anticancer Ther; 2020 Aug; 20(8):715-726. PubMed ID: 32758032
[TBL] [Abstract][Full Text] [Related]
3. Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer.
Inderjeeth AJ; Topp M; Sanij E; Castro E; Sandhu S
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497408
[TBL] [Abstract][Full Text] [Related]
4. Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer.
Adashek JJ; Jain RK; Zhang J
Cells; 2019 Aug; 8(8):. PubMed ID: 31404966
[TBL] [Abstract][Full Text] [Related]
5. Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events.
Madariaga A; Bowering V; Ahrari S; Oza AM; Lheureux S
Int J Gynecol Cancer; 2020 Jul; 30(7):903-915. PubMed ID: 32276934
[TBL] [Abstract][Full Text] [Related]
6. Development of PARP inhibitors in advanced prostate cancer.
Bourlon MT; Valdez P; Castro E
Ther Adv Med Oncol; 2024; 16():17588359231221337. PubMed ID: 38205078
[TBL] [Abstract][Full Text] [Related]
7. Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors.
Faraoni I; Graziani G
Cancers (Basel); 2018 Dec; 10(12):. PubMed ID: 30518089
[TBL] [Abstract][Full Text] [Related]
8. DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies.
Dariane C; Timsit MO
Eur Surg Res; 2022; 63(4):155-164. PubMed ID: 35944490
[TBL] [Abstract][Full Text] [Related]
9. PARP inhibitors in metastatic prostate cancer.
Taylor AK; Kosoff D; Emamekhoo H; Lang JM; Kyriakopoulos CE
Front Oncol; 2023; 13():1159557. PubMed ID: 37168382
[TBL] [Abstract][Full Text] [Related]
10. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
11. Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer.
Maughan BL; Antonarakis ES
Expert Opin Pharmacother; 2021 Aug; 22(12):1625-1632. PubMed ID: 33827356
[TBL] [Abstract][Full Text] [Related]
12. Comparative Analyses of Poly(ADP-Ribose) Polymerase Inhibitors.
Guha M; Sobol Z; Martin M; Hemkens M; Sung T; Rubitski E; Spellman R; Finkelstein M; Khan N; Hu W
Int J Toxicol; 2022 Dec; 41(6):442-454. PubMed ID: 35989659
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer.
Jang A; Sartor O; Barata PC; Paller CJ
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33233320
[TBL] [Abstract][Full Text] [Related]
14. Relevance of poly (ADP-ribose) polymerase inhibitors in prostate cancer.
Rescigno P; Chandler R; de Bono J
Curr Opin Support Palliat Care; 2018 Sep; 12(3):339-343. PubMed ID: 29979319
[TBL] [Abstract][Full Text] [Related]
15. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
Padella A; Ghelli Luserna Di RorĂ A; Marconi G; Ghetti M; Martinelli G; Simonetti G
J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680
[TBL] [Abstract][Full Text] [Related]
16. Advances in PARP Inhibitors for Prostate Cancer.
Tisseverasinghe S; Bahoric B; Anidjar M; Probst S; Niazi T
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980735
[TBL] [Abstract][Full Text] [Related]
17. Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations.
Xu Q; Li Z
Front Pharmacol; 2021; 12():743073. PubMed ID: 34912215
[TBL] [Abstract][Full Text] [Related]
18. PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures.
McNevin CS; Cadoo K; Baird AM; Finn SP; McDermott R
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230674
[TBL] [Abstract][Full Text] [Related]
19. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
[No Abstract] [Full Text] [Related]
20. Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology.
Ziadeh T; Kourie HR
Pharmacogenomics; 2021 Dec; 22(18):1237-1250. PubMed ID: 34729995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]